Alzheimer's Disease and Dementia
Our work in Alzheimer's Disease and Dementia
-
Research, Advocacy, and the Fight Against Alzheimer’s
Join Dana Goldman in conversation with Paul Aisen and Lauren Miller Rogen for a discussion about research, advocacy, and bringing awareness to Alzheimer’s.
-
After Decades of Disappointment, a Turning Point Is Visible in Alzheimer’s Treatment
The USC-Brookings Schaeffer Initiative for Health Policy hosted a webinar featuring national thought leaders to examine hopeful signs in clinical development and policy that will ensure access to treatments and diagnostics.
Categorized in -
NIA-Funded Center Addresses Social, Economic Impacts of Alzheimer’s
The new center will explore innovative ways to ease the disease’s toll on individuals, families and caregivers while also developing strategies to reduce its burden on healthcare systems with an international team of researchers.
-
Blood‐Based Biomarkers for Alzheimer’s Pathology and the Diagnostic Process for a Disease‐Modifying Treatment: Projecting the Impact on the Cost and Wait Times
Blood‐based biomarker tests are a promising tool to improve triaging Alzheimer’s disease at the primary care level.
Categorized in -
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for advances in Alzheimer’s disease made in 2001 and projects future breakthroughs over the next 20 years.
Categorized in -
Overcoming Barriers to Success in Alzheimer’s Disease Clinical Trials
Even modest delays in the progression of Alzheimer’s disease could dramatically alter the current trajectory and generate large health benefits.
Categorized in -
Key Barriers for Clinical Trials for Alzheimer’s Disease
Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.
Categorized in -
Innovation in Alzheimer’s Disease: Policies to Support Access to Treatments, Diagnostics, and Prevention
Join the USC-Brookings Schaeffer Initiative for Health Policy for a webinar that looks at hopeful signs in clinical development and the policy challenges on how to make available Alzheimer’s disease treatments and diagnostics to all those who should have them.
Categorized in -
Pharmaceutical Treatment for Alzheimer’s Disease and Related Dementias: Utilization and Disparities
The use of antidementia drugs is relatively low and varies widely by race/ethnicity.
Categorized in -
Sex, Race, and Age Differences in Prevalence of Dementia in Medicare Claims and Survey Data
This study provides the first comparison of trends in dementia prevalence in the U.S. population using 3 different dementia ascertainments/data sources. They found there are still substantial differences across measures in dementia prevalence among Blacks and Hispanics.